Enhancing insulin sensitivity by reducing adipocyte senescence using uPAR-targeted nanoparticles in high-fat-diet-induced obese mice.
Key claim: uPAR-targeted nanoparticles co-delivering dasatinib and quercetin selectively clear senescent adipocytes and enhance insulin sensitivity in high-fat-diet-induced obese mice.
Abstract
The urokinase-type plasminogen activator receptor (uPAR) is a glycosylphosphatidylinositol-anchored membrane protein that regulates fibrinolysis, cell adhesion, migration, and intracellular signaling. Elevated uPAR expression is linked to numerous pathological conditions, including cancer, inflammation, and metabolic dysfunction. In obesity and aging, increased uPAR levels are associated with chronic inflammation, adipose tissue impairment, and systemic metabolic disturbances. uPAR also modulates adipocyte differentiation and contributes to the progression of inflammatory obesity, while serving as a key regulator of cellular senescence triggered by oncogenic stress, chemotherapy, or aging. These characteristics position uPAR as a compelling therapeutic target for metabolic and age-related diseases. To address this, we developed a nanoparticle-based targeted therapy optimized for senolytic delivery, which enhances accumulation in uPAR-overexpressing cells and improves drug stability. Dasatinib and quercetin, two established senolytic agents, were co-encapsulated into uPAR-targeted hybrid nanoparticles to selectively eliminate senescent cells, reduce inflammation, and restore metabolic homeostasis, presenting a promising therapeutic strategy for obesity- and aging-associated disorders.
Why this matters
Senolytic translation has been bottlenecked by off-target exposure of systemic D+Q; a uPAR-targeted nanoparticle carrier that selectively depletes senescent adipocytes and restores insulin sensitivity in obese mice is a delivery-layer advance on an established intervention class rather than new senescence biology. It also reinforces adipose tissue as a high-value senescent-cell compartment for metabolic aging endpoints, though the gap to a human insulin-sensitivity trial remains wide.